Vertex receives chmp positive opinion for kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor in children with cystic fibrosis ages 6 through 11

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) adopted a positive opinion for the label extension of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor, for the treatment of cystic fibrosis (cf) in patients ages 6 through 11 years old who have at least one f508del mutation in the cystic fibrosis transmembrane conductance r
VRTX Ratings Summary
VRTX Quant Ranking